Career Contact Us Sitemap Search
  Manufacturing Resources Research Global Disease Initiative Investor Relations Strides Worldwide Products Press Room
 
   
 

Anti-tuberculosis products

 

Anti-retroviral drugs

  Anti-malarial drugs
  Anti-retroviral drugs
 

Description

Dosage Form

Packing

Regulatory status

Lamivudine 150mg

Tablet

60’s HDPE Bottle

WHO pre-qualified

Stavudine 30mg/40mg/

HGC

60’s HDPE Bottle

WHO pre-qualified

Nevirapine 200mg

Tablet

60s HDPE bottle

WHO pre-qualified, US FDA tentative approval

Indinavir sulphate 400mg

HGC

120/180 HDPE Bottle

Submitted to WHO

Lamivudine 150mg + Zidovudine 300mg

Tablet

60’s HDPE Bottle

WHO pre-qualified

Lamivudine 150mg + Stavudine 30mg

Tablet

60’s HDPE Bottle

Submitted to WHO. Bio-equivalence accepted

Lamivudine 150mg + Stavudine 40mg

Tablet

60’s HDPE Bottle

WHO pre-qualified

Lamivudine 150mg +stavudine 40mg +nevirapine 200mg

Tablet

60s HDPE Bottle

Submitted to WHO Product quality pre-qualified

Lamivudine 150mg +stavudine 30mg +nevirapine 200mg

Tablet

60s HDPE Bottle

 

Ritonavir 100mg

SGC

60s HDPE bottle

BE study available

Efavirenz 200mg/600mg

Tablet

90s/30s HDPE bottle

BE study in progress

Lamivudine 25mg/50mg

Effervescent granules

Unit dose sachets

 

Stavudine 5mg/10mg

Effervescent granules

Unit dose sachets

 

Nevirapine 25mg/50mg

Effervescent granules

Unit dose sachets

 

Zidovudine 25mg/50mg

Effervescent granules

Unit dose sachets